Details

Autor(en) / Beteiligte

• Sorscher, Steven M

Titel

EGFR Mutations and Sensitivity to Gefitinib

Ist Teil von

• The New England journal of medicine, 2004-09, Vol.351 (12), p.1260-1261

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2004

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• To the Editor: The important study by Dr. Lynch and colleagues (May 20 issue) 1 suggests that specific mutations in the epidermal growth factor receptor (EGFR) characterize a subgroup of non–small-cell lung cancers that may be highly responsive to gefitinib therapy. Do these mutations predict a greater sensitivity to chemotherapy as well? The overall objective response rate to first-line combination chemotherapy for metastatic non–small-cell lung cancer is about 20 percent. 2 Only tumors from a small cohort of patients who had a response to gefitinib were studied for the specific mutations, but all patients except one had also received prior chemotherapy. Although . . .